Literature DB >> 30363600

Clozapine Treatment for Impulse Control Disorders in Parkinson's Disease Patients: A Case Series.

John Liang1, Mark Groves1, Vicki L Shanker1.   

Abstract

Impulse control disorders (ICDs) are nonmotor complications of dopaminergic medications characterized by problems in behavioral self-control. Common management involves discontinuing or lowering dopaminergic medication, often producing motor worsening. We performed a retrospective chart review of Parkinson's disease (PD) patients treated with clozapine for ICDs. Four patients treated with clozapine for ICD were identified. Three patients were men. All 4 took dopaminergic medications at the time that ICDs developed; all received dopamine agonist therapy. ICDs included compulsive shopping, binge drinking, and hypersexuality. All 4 patients had complete resolution of symptoms while taking clozapine (12.5-37.5 mg). Two patients discontinued clozapine because of side effects. Larger studies are needed to further evaluate clozapine's role in treating PD patients with ICD.

Entities:  

Keywords:  ICD; clozapine; impulse; parkinson

Year:  2015        PMID: 30363600      PMCID: PMC6178770          DOI: 10.1002/mdc3.12167

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  10 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Clozapine for medication-related pathological gambling in Parkinson disease.

Authors:  Alessandro Rotondo; Domenico Bosco; Massimiliano Plastino; Arturo Consoli; Francesca Bosco
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

3.  Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.

Authors:  H H Fernandez; R Durso
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

4.  Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.

Authors:  R M Trosch; J H Friedman; M C Lannon; R Pahwa; D Smith; L C Seeberger; C F O'Brien; P A LeWitt; W C Koller
Journal:  Mov Disord       Date:  1998-05       Impact factor: 10.338

Review 5.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

6.  Pathological gambling in Parkinson disease is reduced by amantadine.

Authors:  Astrid Thomas; Laura Bonanni; Francesco Gambi; Angelo Di Iorio; Marco Onofrj
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

7.  Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.

Authors:  E S Burstein; J Ma; S Wong; Y Gao; E Pham; A E Knapp; N R Nash; R Olsson; R E Davis; U Hacksell; D M Weiner; M R Brann
Journal:  J Pharmacol Exp Ther       Date:  2005-08-31       Impact factor: 4.030

8.  Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.

Authors:  Daniel Weintraub; Mandy Sohr; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

9.  Prospective cohort study of impulse control disorders in Parkinson's disease.

Authors:  Jesse Bastiaens; Benjamin J Dorfman; Paul J Christos; Melissa J Nirenberg
Journal:  Mov Disord       Date:  2013-01-02       Impact factor: 10.338

10.  Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.

Authors:  Kimberly Papay; Sharon X Xie; Matthew Stern; Howard Hurtig; Andrew Siderowf; John E Duda; James Minger; Daniel Weintraub
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.